What Davos Alzheimer's Collaborative does

Davos Alzheimer's Collaborative (DAC) is a nonprofit multi-stakeholder partnership founded in 2021 and co-convened by the World Economic Forum and The Global CEO Initiative on Alzheimer's Disease, headquartered in Switzerland with a U.S. 501(c)(3) affiliate in Wayne, Pennsylvania. Its mission is to mount a coordinated global response to Alzheimer's disease by accelerating drug development and preparing healthcare systems to deliver new innovations. DAC organizes its work around three core programs: Global Cohorts (building a one-million-person globally diverse research cohort, with 12 cohorts already linked across Africa, Asia, and South America), Global Clinical Trials (linking 90+ trial sites in North America with European and global partners through a technology platform to reduce time and cost of trials), and Healthcare System Preparedness (implementing early detection and diagnosis programs across 70+ sites in 19 countries and 5 continents using digital cognitive assessments and blood-based biomarkers).

The technology stack combines digital cognitive assessment tools (Linus Health, Cogstate Cognigram, Cognivue Clarity) and blood-based biomarker testing (C2N PrecivityAD) for early detection, supported by a centralized implementation infrastructure including the Early Detection Blueprint and the Brain Health Navigator Toolkit. In February 2026, DAC expanded a collaboration with FINGERS Brain Health Institute on FINGERPRINT, an agentic AI system that integrates multiomic, digital, clinical, and population-level prevention trial data to enable globally representative predictive modeling. Complementary initiatives include The Brain House (a convening platform launched at WEF 2025), the Africa Task Force on Brain Health and its 6x5 Plan (launched November 2025 at a G20 event in Johannesburg), and the 2026 Global South Diversity Strategy with LifeArc, Our Future Health, and the Alzheimer's Disease Data Initiative.

DAC's business model is that of a globally funded nonprofit initiative. Revenue derives from philanthropic donations, grants, and in-kind contributions from pharmaceutical companies (Eli Lilly, Roche, Biogen, Eisai, Otsuka), diagnostics companies (C2N, Linus Health, Cogstate, Cognivue), and institutional funders including TMCity, LifeArc, ADDI, and the Gates Foundation. The organization has stated an aspiration to invest over $700 million over time; the confirmed foundational phase closed at $25 million in 2021, followed by $4.5 million in early detection grants deployed in 2022 and additional multi-million-dollar partnership commitments since. There is no product pricing; DAC coordinates resources, research, and policy work rather than selling goods or services.

Name

Davos Alzheimer's Collaborative

Legal name

Davos Alzheimer's Collaborative

Website

https://davosalzheimerscollaborative.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Davos Alzheimer's Collaborative is a nonprofit multi-stakeholder partnership that accelerates Alzheimer's drug development and healthcare system preparedness globally by building diverse research cohorts, linking clinical trial networks, and deploying early detection programs across 19 countries.

Ownership category

akta.pro rank

Product category

Alzheimer's Research Coordination and Global Health Collaboration

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industry

Health Systems Strengthening & Universal Health Coverage (UHC) Partnerships (HLAJAOAL)

Keywords

• Alzheimer's research coordination
• Global clinical trials
• Healthcare system preparedness
• Brain health collaboration
• Diverse research cohorts

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Philanthropic Donations and Grants: DAC operates as a nonprofit initiative funded by private sector, government, and philanthropic contributions. The organization has received support from pharmaceutical companies including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, and others. DAC was launched with a goal to invest over $700 million to accelerate innovation in drug development.
2. In-Kind Contributions: DAC receives invaluable contributions of time and talent from supporters including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, C2N, Cognivue, Linus Health, and Cogstate.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

The Davos Alzheimer's Collaborative (DAC) is a global multi-stakeholder nonprofit initiative that coordinates worldwide efforts to accelerate Alzheimer's disease research, drug development, and healthcare system preparedness. DAC operates three core programs: Global Cohorts (building diverse research cohorts across underrepresented populations), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (improving early detection and diagnosis). DAC convenes governments, pharmaceutical companies, researchers, and patient organizations to drive evidence-based changes in policy and practice.

Product overview

The Davos Alzheimer's Collaborative is a pioneering worldwide initiative to cure Alzheimer's disease and improve brain health, organized around three core programs: Global Cohorts (diversifying genetic data for breakthroughs), Global Clinical Trials (linking trial sites worldwide to accelerate drug development), and Healthcare System Preparedness (preparing healthcare systems to deliver innovations). Key initiatives include The Brain House (a global convening platform for brain health policy), the Africa Task Force on Brain Health's 6x5 Plan, and practical tools like the Early Detection Blueprint and Brain Health Navigator Toolkit. The organization serves as a coordinator rather than a product vendor, extending global research into the Global South where the majority of Alzheimer's cases exist.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Cohorts Global Cohorts is a DAC program that builds diverse research cohorts across underrepresented populations to provide high-quality data as the foundation for identifying new biomarkers and developing targeted Alzheimer's treatments. DAC is working to build a cohort of one million people reflecting the disease in all its global diversity, having linked 12 cohorts spanning Africa, Asia, and South America with 20+ additional cohorts under consideration.
• Global Clinical Trials Global Clinical Trials is a DAC program that builds a global clinical trial network and technology platform linking trial sites around the world to reduce the time and cost of Alzheimer's clinical trials, connect researchers worldwide, and accelerate drug development. DAC is linking 90 trial sites in North America with over a dozen in Europe while surveying site capacity to extend future trials globally.
• Healthcare System Preparedness Healthcare System Preparedness is a DAC program that invests in healthcare systems and solution providers to improve rates of early, accurate Alzheimer's diagnosis and ensure healthcare systems worldwide are prepared to deliver new innovations. Includes 70 sites across 19 countries and 5 continents with pilot implementations of digital cognitive assessments and blood biomarker testing.
• The Brain House The Brain House is a global platform hosted by DAC that convenes leaders across healthcare, finance, government, and technology to translate ideas into action on brain health. Hosted at the WEF Annual Meeting in Davos, G7, G20, and UNGA, it positions brain health as a strategic economic priority.
• Africa Task Force on Brain Health (6x5 Plan) The Africa Task Force on Brain Health is a multi-level, multisectoral coalition uniting experts from Africa's five geopolitical regions through six working groups to accelerate brain health innovation across the continent. The 6x5 Plan is a five-year Brain Health Action Plan launched in 2025 to promote brain health and economic growth across Africa.
• FINGERPRINT AI System Collaboration The FINGERPRINT collaboration is an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The system enables globally representative AI modeling by integrating DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling that is biologically, culturally, and environmentally generalizable.
• Brain Health Navigator Program Brain Health Navigator is a DAC program providing resources for patients and providers to support intuitive coordination along the brain-health pathway, spanning frontline patient interactions through diagnosis. Launched at six sites across the U.S.

Quantifiable outcome

• 3x increase in dementia cases projected by 2050 (to 139 million)
• +3 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

21 partnerships are on record, tiered major, core and minor.

• LifeArcmajorStrategic or Co-development Partner · 6 April 2026Partnership to embed diversity as a foundational principle in global dementia research, developing lower-cost diagnostics such as finger-prick blood tests and AI-driven voice analysis tools.
• FINGERS Brain Health Institute (FBHI)coreStrategic or Co-development Partner · 23 February 2026Expanded global collaboration to advance AI-driven discovery for Alzheimer's prevention, centered on FINGERPRINT—an agentic AI system designed to integrate multiomic, digital, clinical, and population-level prevention trial data. The partnership integrates DAC's Global Cohorts data into FINGERPRINT's analytical workflows to support predictive modeling.
• World Economic Forum (WEF)coreStrategic or Co-development Partner · 20 January 2021WEF co-convened and co-founded DAC, providing the platform and network to launch this global initiative. WEF continues to serve as a key convening partner, hosting DAC's activities at the WEF Annual Meeting in Davos.
• Global CEO Initiative on Alzheimer's Disease (CEOi)coreStrategic or Co-development PartnerCEOi co-convened and co-founded DAC alongside WEF. CEOi brings together private sector executives to drive innovation in Alzheimer's research and care.
• Our Future HealthmajorStrategic or Co-development PartnerPartner in the 2026 strategy to diversify data in global dementia research, particularly addressing the gap where 90% of genome-wide association study data comes from European ancestry populations.
• Alzheimer's Disease Data InitiativemajorStrategic or Co-development PartnerGates-funded initiative partnering with DAC to develop lower-cost diagnostics and accelerate brain health research, particularly in underrepresented Global South populations.
• Science for Africa Foundation (SFA Foundation)coreStrategic or Co-development PartnerCollaboration launched to harness AI for brain health across Africa, advancing the Africa Task Force on Brain Health initiatives and the 6x5 Plan for continental brain health innovation.
• Aga Khan University (Brain and Mind Institute)coreStrategic or Co-development PartnerLaunched first Alzheimer's research initiative in East Africa, conducting cohort research study and clinical trial. Partnership addresses lack of diversity in Alzheimer's research and aims to improve care and increase access to treatments throughout Africa.
• California Institute for Regenerative Medicine (CIRM)majorStrategic or Co-development PartnerReleased statement of interest to work with DAC on shared mission to accelerate discovery and delivery of precision therapeutic interventions for brain diseases including Alzheimer's. CIRM brings $5.5 billion in funding and more than 150 active stem cell programs.
• C2N DiagnosticsmajorTechnology or IntegrationProvided the PrecivityAD blood-based biomarker test for DAC's early detection pilot sites. This test aids in accurate diagnosis of Alzheimer's disease and reduces need for expensive, hard-to-access advanced tests.
• Linus HealthmajorTechnology or IntegrationDigital cognitive assessment tool (Core Cognitive Evaluation) provided to DAC pilot sites, reducing need for broad neuropsychological testing. Can be administered via tablet in patient's home.
• CogstatemajorTechnology or IntegrationProvided Cognigram digital cognitive assessment to DAC pilot sites as part of the innovative early detection effort using cutting-edge technology.
• CognivuemajorTechnology or IntegrationProvided Cognivue Clarity digital cognitive assessment to DAC programs, including the Avant Institute grant project for pharmacy-based cognitive screening in rural and underserved communities.
• Global Alzheimer's PlatformmajorStrategic or Co-development PartnerPartnership to link clinical trial sites and accelerate Alzheimer's research. Working with DAC to expand trial networks from North America into Europe and other regions.
• International One Hundred K+ Cohorts Consortium (IHCC)coreStrategic or Co-development PartnerWorking with IHCC to build a cohort of one million people reflecting the disease in all its global diversity. DAC has linked 12 cohorts spanning Africa, Asia and South America with more under consideration.
• CatalightmajorGTM or Marketing PartnerPartner for Brain House 2026. Catalight brings expertise in value-based care for autism and intellectual/developmental disability services, aligning with brain health initiatives.
• EQT Life SciencesmajorGTM or Marketing PartnerPartner for Brain House 2026, contributing to the global platform advancing brain health, cognitive resilience, and economic growth.
• LifeArcmajorGTM or Marketing PartnerPartner for Brain House 2026, supporting the global initiative to advance brain health as a strategic economic priority.
• Wyss CenterminorGTM or Marketing PartnerPartner for Brain House 2026, contributing to the global platform for brain health innovation.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO serves as technical advisor on DAC's healthcare system preparedness efforts. WHO Director-General Tedros Adhanom Ghebreyesus delivered keynote at Brain House during WEF 2026. WHO was first global organization to recognize Alzheimer's as a global health threat.
• Dementias Platform UKmajorStrategic or Co-development PartnerLed the U.K. Early Detection Program to transform early detection by integrating digital cognitive tools into routine clinical care through the READ-OUT study with 10 U.K. healthcare systems.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BrightFocus Foundation: A nonprofit that funds research on Alzheimer's, macular degeneration, and glaucoma. Comparable to DAC as a disease-focused voluntary health organization issuing research grants and convening scientific communities around brain disorders.
• UsAgainstAlzheimer's: An advocacy and policy nonprofit driving national action on Alzheimer's, and parent of CEOi. Comparable to DAC as a multi-stakeholder Alzheimer's advocacy organization with global ambition and pharma/industry ties.
• Alzheimer's Association: The largest U.S. nonprofit dedicated to Alzheimer's care, support, and research. Highly comparable as a disease-specific voluntary health organization driving advocacy, research funding, and care system improvements for Alzheimer's patients and families.
• Alzheimer's Drug Discovery Foundation (ADDF): A nonprofit that funds translational Alzheimer's drug discovery and diagnostics research globally. Directly comparable to DAC as a funder and convener of Alzheimer's R&D with strong ties to pharmaceutical and biotech sponsors.
• Global Alzheimer's Platform Foundation: A clinical trial network organization that links Alzheimer's trial sites across North America and is a direct DAC partner. Comparable as a clinical-trial-focused infrastructure provider accelerating Alzheimer's drug development.
• Alzheimer's Disease Data Initiative (ADDI): A Gates-funded initiative partnering with DAC on data sharing and lower-cost diagnostics for dementia. Directly comparable as a global data and research infrastructure nonprofit targeting Alzheimer's and dementia.

Broad incumbents

• World Health Organization (WHO): The UN's global health authority that serves as DAC's technical advisor and recognized Alzheimer's as a global health threat. Comparable as the convener of international health policy and standards that DAC's healthcare system preparedness programs align with.
• Global CEO Initiative on Alzheimer's Disease (CEOi): The private-sector coalition that co-founded and convenes DAC, bringing together executives to drive Alzheimer's innovation. Highly comparable as a senior-level multi-stakeholder convening body focused on accelerating Alzheimer's breakthroughs.

Others

• GAVI, the Vaccine Alliance: A public-private global health partnership explicitly cited by DAC as the operational archetype for its global coordination mechanism. Comparable as a multi-stakeholder alliance mobilizing large-scale capital and delivery capacity for global health.
• CEPI (Coalition for Epidemic Preparedness Innovations): A multi-stakeholder global partnership — explicitly cited by Margaret Chan and DAC as the structural model for DAC. Comparable as a global convening and funding mechanism accelerating R&D against a major health threat.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/DavosAlzheimer
• LinkedInlinkedin.com/company/davosalzheimers

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Davos Alzheimer's Collaborative